Antibody drug tech firm AbCellera raises $105 million as it works on COVID-19

(Reuters) - Canadian drug discovery technology company AbCellera, which analyzes and identifies antibodies for pharmaceutical companies working on a coronavirus treatment and other medicines, said on Wednesday it had raised $105 million in funds.AbCellera has been working with pharmaceutical firm Eli Lilly and Co which is developing a coronavirus drug based on antibodies from patients that have recovered from the disease. AbCellera uses computer vision and machine learning to quickly analyse..